ETON · Eton Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio
$51.25
-7.94 (-13.41%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$1.65B
Shares
28.58M
Volume · Sep 30
1.81M
Avg daily vol (3M)
559.94K
Eton Pharmaceuticals, Inc. Earnings Call Transcripts
Quarterly earnings calls for Eton Pharmaceuticals, Inc. (ETON), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲315.4%
$3.22M
−$3.04M
'22 Q3
22-11-10
▲39.5%
$8.50M
$912,000
'22 Q4
23-03-16
▲143.8%
$5.30M
−$2.66M
'23 Q1
23-05-11
▲63%
$12.00M
$4.56M
'23 Q2
23-08-10
▲118.3%
$7.03M
−$579,000
'23 Q3
23-11-09
▼13.9%
$7.31M
−$2.26M
'23 Q4
24-03-14
▲50.2%
$7.97M
−$811,000
'24 Q1
24-05-09
▼24.4%
$9.07M
−$3.04M
'24 Q2
24-08-08
▲46.9%
$10.32M
$627,000
'24 Q3
24-11-12
▲59.3%
$11.65M
−$598,000
'24 Q4
25-03-18
▲116.9%
$17.28M
−$1.57M
'25 Q1
25-05-13
▲108.6%
$18.93M
−$2.58M
'25 Q2
25-08-07
▲117.5%
$22.46M
−$1.93M
'25 Q3
25-11-06
▲82.7%
$21.28M
$1.48M
'25 Q4
26-03-19
▲40.4%
$24.27M
$1.55M
'26 Q1
26-05-14
LATEST
▲98.6%
$37.59M
$11.58M
'26 Q2
26-08-13
Earnings call
FY26 · Q2
2026-08-13
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
Confident tone
Pediatric dermatology franchise and ASN-001
Pipeline and label expansion
Margin expansion and profitability
Revenue
$37.59M
▲ 98.6% YoY Diluted EPS
$0.35
Gross margin
67.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Eton Pharmaceuticals, Inc. (ETON) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-14
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Confident tone
Product launches
Rare disease portfolio diversification
Hemangiol acquisition and patient transition
Revenue
$24.27M
▲ 40.4% YoY Diluted EPS
$0.05
Gross margin
60.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript
Confident tone
Financial results and growth
Desmota launch
Clinical development pipeline
Revenue
$21.28M*
▲ 82.7% YoY Gross margin
61.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Eton Pharmaceuticals, Inc. (ETON) Q3 2025 Earnings Call Transcript
Confident tone
KHINDIVI launch and reformulation
Label expansion and clinical pipeline
Pricing and gross margin outlook
Revenue
$22.46M
▲ 117.5% YoY Diluted EPS
$-0.07
▼ 450% YoY Gross margin
35.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript
Confident tone
Increlex acquisition performance and patient growth
Khindivi FDA approval and launch
ET-600 NDA submission and PDUFA
Revenue
$18.93M
▲ 108.6% YoY Diluted EPS
$-0.10
Gross margin
63.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript
Confident tone
ET-400 (liquid hydrocortisone) approval and launch
Increlex relaunch and patient growth
Galzin and Wilson disease franchise
Revenue
$17.28M
▲ 116.9% YoY Diluted EPS
$-0.06
Gross margin
57.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Eton Pharmaceuticals, Inc. (ETON) Q4 2024 Earnings Call Transcript
Confident tone
2025 Financial Outlook and Ramp Expectations
Acrolex / Galzum Acquisition
Adrenal Insufficiency Franchise (Alkindi/ET400)
Revenue
$11.65M*
▲ 59.3% YoY Gross margin
55.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
Confident tone
Pipeline and ET-400
Increlex Acquisition
Metabolic Portfolio
Revenue
$10.32M
▲ 46.9% YoY Diluted EPS
$0.02
Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript
Confident tone
Product sales growth and streak
ET-400 pipeline and NDA
Carglumic Acid and metabolic portfolio
Revenue
$9.07M
▼ 24.4% YoY Diluted EPS
$-0.12
▼ 166.7% YoY Gross margin
62.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Eton Pharmaceuticals, Inc. (ETON) Q1 2024 Earnings Call Transcript
Confident tone
ET-400 NDA submission and launch
ALKINDI SPRINKLE performance and discontinuation
PKU GOLIKE acquisition
Revenue
$7.97M
▲ 50.2% YoY Diluted EPS
$-0.03
Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript
Confident tone
Revenue growth and commercial momentum
ET-400 pipeline and liquid hydrocortisone
Business development and acquisitions
Revenue
$7.31M*
▼ 13.9% YoY Gross margin
49.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Eton Pharmaceuticals, Inc. (ETON) Q3 2023 Earnings Call Transcript
Revenue
$7.03M
▲ 118.3% YoY Diluted EPS
$-0.02
Gross margin
62.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Eton Pharmaceuticals, Inc. (ETON) Q2 2023 Earnings Call Transcript
Revenue
$12.00M
▲ 63% YoY Diluted EPS
$0.18
Gross margin
80.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Eton Pharmaceuticals, Inc. (ETON) Q1 2023 Earnings Call Transcript
Revenue
$5.30M
▲ 143.8% YoY Diluted EPS
$-0.10
Gross margin
63.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Eton Pharmaceuticals, Inc. (ETON) Q4 2022 Earnings Call Transcript
Revenue
$8.50M*
▲ 39.5% YoY Gross margin
74.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Eton Pharmaceuticals, Inc. (ETON) Q3 2022 Earnings Call Transcript
Revenue
$3.22M
▲ 315.4% YoY Diluted EPS
$-0.12
Gross margin
62.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Eton Pharmaceuticals, Inc. (ETON) Q2 2022 Earnings Call Transcript
Revenue
$7.36M
▲ 139.9% YoY Diluted EPS
$-0.06
Gross margin
62.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Eton Pharmaceuticals, Inc. (ETON) Q1 2022 Earnings Call Transcript
Revenue
$2.18M
▼ 81.7% YoY Diluted EPS
$-0.21
▼ 210.5% YoY Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-16
Eton Pharmaceuticals, Inc. (ETON) Q4 2021 Earnings Call Transcript
Revenue
$6.09M*
▲ 7422.2% YoY Gross margin
93.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Eton Pharmaceuticals, Inc. (ETON) Q3 2021 Earnings Call Transcript
Revenue
$775,000
Diluted EPS
$-0.24
Gross margin
15.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Eton Pharmaceuticals, Inc. (ETON) Q2 2021 Earnings Call Transcript
Revenue
$3.07M
▲ 15235% YoY Diluted EPS
$-0.08
Gross margin
94.3%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Eton Pharmaceuticals, Inc. (ETON) Q1 2021 Earnings Call Transcript
Revenue
$11.90M
▲ 11917.2% YoY Diluted EPS
$0.19
Gross margin
86.6%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Eton Pharmaceuticals, Inc. (ETON) Q4 2020 Earnings Call Transcript
Revenue
$81,000*
▼ 82.4% YoY Gross margin
-455.6%
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Eton Pharmaceuticals, Inc. (ETON) Q3 2020 Earnings Call Transcript
Revenue
$
Gross margin
10.6%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-12
Eton Pharmaceuticals, Inc. (ETON) Q2 2020 Earnings Call Transcript
Revenue
$20,000
Diluted EPS
$-0.23
Gross margin
-40.0%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
Eton Pharmaceuticals, Inc. (ETON) Q1 2020 Earnings Call Transcript
Revenue
$99,000
▼ 80.2% YoY Diluted EPS
$-0.50
Gross margin
-3.0%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-06
Eton Pharmaceuticals, Inc. (ETON) Q4 2019 Earnings Call
Revenue
$459,000
Rev · 2q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls